Friday, August 18, 2017 12:33:00 PM
this may be the reason for the shelf registration..........
let's hope BARDA funds the study, if not, we dilute......imhop
from article:
According to management, BARDA could come to a decision by the end of 2017 and, if approved, would fully fund the estimated $30M cost of the pivotal study. Currently, we expect this pivotal study to complete by mid-2018 and the US government may begin stockpiling of PLX-R18 as early as 3Q18.”
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM